Home Cart Sign in  
Chemical Structure| 877963-94-5 Chemical Structure| 877963-94-5

Structure of LOC14
CAS No.: 877963-94-5

Chemical Structure| 877963-94-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LOC14 is a high affinity protein disulfide isomerase (PDI) modulator with Kd of 62 nM.

Synonyms: LOC14

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LOC14

CAS No. :877963-94-5
Formula : C16H19N3O2S
M.W : 317.41
SMILES Code : O=C1N(CN2CCN(C(C3CC3)=O)CC2)SC4=C1C=CC=C4
Synonyms :
LOC14
MDL No. :MFCD07849042
InChI Key :YVBSNHLFRIVWFQ-UHFFFAOYSA-N
Pubchem ID :9117962

Safety of LOC14

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312-P330-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Candida albicans 3153A 100 µM 48 hours LOC14 inhibited the growth of Candida albicans. PMC11077991
Candida albicans TFPY2307 100 µM 48 hours LOC14 inhibited the growth of Candida albicans. PMC11077991
Candida albicans TFPY412 100 µM 48 hours LOC14 inhibited the growth of Candida albicans. PMC11077991
Candida albicans GDH2346 100 µM 48 hours LOC14 inhibited the growth of Candida albicans. PMC11077991
Candida albicans SC5314 100 µM 48 hours LOC14 inhibited the growth of Candida albicans with an MIC of 31.3 µM. PMC11077991
PC12 cells 4, 1, and 0.25 μg/mL 48 hours To screen compounds that could rescue PC12 cell viability, LOC14 showed potency with EC50=500 nM PMC4418888
Primary mouse tracheal epithelial cells (MTECs) 10 μM 24 hours LOC14 treatment inhibited PDIA3 activity, reduced the number of influenza nucleoprotein (NP) positive cells, indicating that LOC14 can inhibit viral replication. PMC6365984
Mouse tracheal epithelial cells (MTECs) 10 μM 1 hour pretreatment, 2 hours post-infection LOC14 decreased NA oligomerization and activity, reduced viral burden and inflammatory response. PMC8834910
A549 cells 10 μM 1 hour pretreatment, 2 hours post-infection LOC14 significantly decreased cell death, NA production, disulfide bonds, and activity, as well as inflammatory response. PMC8834910
Osteoclast precursor cells (OPCs) 5 μM 24 hours LOC14 inhibited the expression of osteoclast differentiation-related genes (Traf6, Nfatc1) and function-related genes (Ctsk), and suppressed osteoclast differentiation by interfering with calcium oscillation. PMC11336591
Bone marrow-derived macrophages (BMMs) 0.3125, 0.625, 1.25, 2.5, 5 μM 24 hours Assessed cytotoxicity of LOC14 on BMMs, showing no significant toxicity at concentrations ranging from 0.3125 to 10 μM. PMC11336591
VDR KO mouse corneal fibroblasts (MCF) 20 μM 24 hours To investigate the effect of LOC14 on 1,25-Vit D3 and 24,25-Vit D3-induced CYP24A1 and CYP27B1 expression. Results showed that LOC14 completely blocked the promoting effects of 1,25-Vit D3 and 24,25-Vit D3 on CYP24A1 and CYP27B1 expression. PMC8363511
VDR WT mouse corneal fibroblasts (MCF) 20 μM 24 hours To investigate the effect of LOC14 on 1,25-Vit D3 and 24,25-Vit D3-induced CYP24A1 and CYP27B1 expression. Results showed that LOC14 significantly attenuated the promoting effects of 1,25-Vit D3 and 24,25-Vit D3 on CYP24A1 and CYP27B1 expression. PMC8363511
Human corneal fibroblasts (HCF) 10 μM 24 hours To investigate the effect of LOC14 on 1,25-Vit D3 and 24,25-Vit D3-induced CYP24A1 and CYP27B1 expression. Results showed that LOC14 had no significant effect on CYP24A1 and CYP27B1 expression in human corneal fibroblasts. PMC8363511
STHdhQ111/111 cells 5-40 nM 48 hours LOC14 significantly protected cells from mHtt-induced ATP level reduction PMC5905666

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6j mice Wild-type Intravenous or oral 20 mg/kg Single dose To evaluate the BBB penetration of LOC14, results showed that LOC14 could penetrate the BBB and accumulate in the brain PMC4418888
C57BL/6NJ mice Influenza virus infection model Intraperitoneal injection 50 mg/kg 1 hour before infection, 24 or 48 hours post-infection LOC14 significantly reduced viral burden, NA activity, and inflammatory response. PMC8834910
C57BL/6J female mice Ovariectomy (OVX)-induced osteoporosis model Intraperitoneal injection 5 mg/kg Every other day for four weeks LOC14 alleviated OVX-induced bone loss and partially reversed osteogenic impairment caused by OVX. PMC11336591
Mice N171–82Q HD mouse model Oral 20 mg/kg/day Once daily, starting from 12 weeks of age until the end of the study LOC14 significantly improved motor function, attenuated brain atrophy, extended survival, and suppressed ER stress PMC5905666

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.15mL

0.63mL

0.32mL

15.75mL

3.15mL

1.58mL

31.50mL

6.30mL

3.15mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories